ArticleScientific reports2025
SARS-CoV-2 spike mutations alter structure and energetics to modulate ACE2 binding immune evasion and viral adaptation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Target-Based Antiviral Drug Development Against Human Respiratory Viruses.Pathogens (Basel, Switzerland) · 2026Review
- Nanobodies targeting SARS-CoV-2 variants.Acta pharmaceutica Sinica. B · 2026Review
- Different mechanisms for human rhinovirus survival in the presence of deleterious amino acid substitutions at virion protein-protein or RNA-protein interfaces.Journal of virology · 2026Article
- Furin as a Novel Pan-Viral Therapeutic Target: Implications for Dengue and SARS-CoV-2.Viruses · 2026Review
- ViralBindPredict: empowering viral protein-ligand binding sites through deep learning and protein sequence-derived insights.GigaScience · 2026Article
- The emergence of putative epistatic mutations and iSNVs in SARS-CoV-2 XBB.1.16 variants linked with alteration in immunogenic determinants.Frontiers in immunology · 2026Article
- Vaccination-driven evolution of infectious bronchitis virus in Korea: implication for the control of other coronavirus infections.Frontiers in veterinary science · 2026Review
- Comprehensive whole-genome characterization of SARS-CoV-2 strains in Jining China 2024-2025.Frontiers in microbiology · 2026Article
- Detailed investigation of B cell populations following vaccination and infection with severe acute respiratory syndrome coronavirus-2 during pregnancy.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The persistent evolution of SARS-CoV-2 is driven by mutations in the spike protein that modulate receptor binding, immune evasion, and structural stability. In this study, we deciphered the complex host-virus protein-protein interactions using an integrated molecular dynamics (MD) approach to assess the biophysical impacts of key spike mutations, including T478K, T478A, T478E, E484K, G496S, F490S, Q493E, and Y369C. Our findings reveal that viral adaptation hinges on trade-offs between transmissibility and immune escape. For instance, T478K enhances ACE2 binding through structural rigidification and salt bridge formation (e.g., K478-D30), favoring Omicron's increased transmissibility. In contrast, T478A introduces polarity loss and interface relaxation, while T478E leads to electrostatic repulsion and weakened binding, both of which compromise interface stability. E484K balances antibody evasion (e.g., against LY-CoV555) with receptor stabilization via compensatory interactions (e.g., K484-D38). In vivo studies support these findings, showing that T478K and E484K enhance viral fitness and immune evasion in animal models. Mutations like G496S and F490S act as stealth adaptations, subtly destabilizing ACE2 or introducing metastability without fully disrupting binding. The high-risk Y369C mutation collapses the N-terminal domain supersite, enhancing immune evasion but requiring compensatory mutations (e.g., G142D) to maintain viability. Evolutionary strategies favor co-mutations (e.g., T478K + Q498R) that distribute fitness costs across residues. Notably, functionally conserved energetic hotspots such as T430, L390, V382, K386, F486, Q493 (RBD), and Q102, R192 (ACE2) consistently contributed to ACE2 engagement across all variants, representing potential targets for broad-spectrum therapeutics. Our work provides the importance of real-time surveillance for mutations that exploit conformational flexibility or compensatory networks, informing the design of durable vaccines and multi-specific antibodies. These insights bridge molecular mechanisms with evolutionary dynamics, offering a framework to anticipate and counter emerging variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.